Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the acquisition and launch1 of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. Glenmark's Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials can be expected to have the same therapeutic effect as the listed drug product upon which the Agency relied as the basis of safety and effectiveness, Acetadote®2 Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc. Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc.

According to IQVIATM sales data for the 12-month period ending January 2025, the Acetadote® Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials market2 achieved annual sales of approximately $15.2 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the U.S. market as we continue to drive growth for the hospital segment."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1311.55 as compared to the previous close of Rs. 1278.75. The total number of shares traded during the day was 10928 in over 1038 trades.

The stock hit an intraday high of Rs. 1318.80 and intraday low of 1275.10. The net turnover during the day was Rs. 14191888.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USALaunch AcetylcysteineInjection